Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Rescue Plan Act of 2021
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
ANPRM International Pricing Index Model for Medicare Part B Drugs. Issues relating to Medicare Part D and Part B pricing reform. Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs. H.R.1319, the American Rescue Plan Act (Section 9816, Sunset of Limit on Maximum Rebate Amount for Single Source Drugs and Innovator Multiple Source Drugs).
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2021 · second_quarter · Q2
Issues related to Medicare Parts B and D pricing reform. S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act. Issues related to CMS rulemaking [CMS-4190-F3, CMS-2482-P2].
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2021 · first_quarter · Q1
Source: Senate LDA
Issues related to Medicare Parts B and D pricing reform. S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act. Issues related to CMS rulemaking [CMS-4190-F3, CMS-2482-P2].
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D Coverage and Reimbursement Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-Based Purchasing for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability Requirements * Medicaid and 340B issues & drug discount program *Importation and Most Favored Nations * NTAP/IPPS Rule
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Value Based Arrangements
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model (VBAs) Price Transparency Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D & B Coverage and Reimbursement Legislative proposals to change Medicare Part D Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization * Medicaid and 340B issues & drug discount program *Importation and Most Favored Nations * H.R.8845, Medicare Multi-Cancer Early Detection Screening Coverage Act of 2020
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Consolidated Appropriations Act, 2021
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Drug Pricing Transparency S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages * Healthcare policy & reimbursement *FY2021 Omnibus and COVID Relief and Response Act - H.R. 133, H. Rules Comm. Print 116-68 *Discussions related to a possible increase in the Federal average manufactures price cap
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model (VBAs) Price Transparency Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Protecting Consumer Access to Generic Drugs Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Preserve Access to Affordable Generics and Biosimilars Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2020
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D & B Coverage and Reimbursement Legislative proposals to change Medicare Part D Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization * Medicaid and 340B issues & drug discount program *Importation and Most Favored Nations * H.R.8845, Medicare Multi-Cancer Early Detection Screening Coverage Act of 2020
Affordable Prescriptions for Patients Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model (VBAs) Price Transparency Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Affordable Prescriptions for Patients Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs
Affordable Prescriptions for Patients Act of 2019
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Lower Health Care Costs Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Drug Pricing Transparency S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages * Healthcare policy & reimbursement *FY2021 Omnibus and COVID Relief and Response Act - H.R. 133, H. Rules Comm. Print 116-68 *Discussions related to a possible increase in the Federal average manufactures price cap
Lower Health Care Costs Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Drug Pricing Transparency Personalized Medicine Diagnostics S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages Telehealth
Lower Health Care Costs Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Drug Pricing Transparency The CARES Act and funding bills S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages Telehealth * Healthcare policy & reimbursement
Preserve Access to Affordable Generics and Biosimilars Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs
Issues related to the 340B drug discount program. Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form-e-labeling.
Issues related to drug pricing. COVID-19 vaccine and therapy development.
ANPRM International Pricing Index Model for Medicare Part B Drugs. Issues relating to Medicare Part D and Part B pricing reform. Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs. H.R.1319, the American Rescue Plan Act (Section 9816, Sunset of Limit on Maximum Rebate Amount for Single Source Drugs and Innovator Multiple Source Drugs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2020 · fourth_quarter · Q4
Medicare Part D & B Coverage and Reimbursement Legislative proposals to change Medicare Part D Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization * Medicaid and 340B issues & drug discount program *Importation and Most Favored Nations * H.R.8845, Medicare Multi-Cancer Early Detection Screening Coverage Act of 2020
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model (VBAs) Price Transparency Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Supply chain & Buy American issues (COVID-19 related) Importation
Value of Prescription Drugs Drug Pricing Transparency S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages * Healthcare policy & reimbursement *FY2021 Omnibus and COVID Relief and Response Act - H.R. 133, H. Rules Comm. Print 116-68 *Discussions related to a possible increase in the Federal average manufactures price cap
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2020 · third_quarter · Q3
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ANPRM: Importation of Prescription drugs and Most Favored Nations
Medicare Part D Coverage and Reimbursement Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-Based Purchasing for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability Requirements * Medicaid and 340B issues & drug discount program *Importation and Most Favored Nations * NTAP/IPPS Rule
Supply chain & Buy American issues (COVID-19 related) Importation
Value of Prescription Drugs Drug Pricing Transparency The CARES Act and funding bills S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages Telehealth * Healthcare policy & reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2020 · second_quarter · Q2
Value of Prescription Drugs Drug Pricing Transparency Personalized Medicine Diagnostics S. 1895, Lower Health Care Costs Act COVID-19 Vaccine and Therapy Development COVID-19 response packages Telehealth
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicaid drug pricing reporting H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs ESRD PPS, Medicare coverage ANPRM International Pricing Index Model for Medicare Part B Drugs Proposed Rule: Medicaid Program: Establishing Minimum Standards in Medicaid State Drug Utilization Value Based Arrangements
Trade Issues Supply chain & Buy American issues (COVID-19 related) Importation
Medicare Part D coverage and reimbursement Value of Prescription Drugs Innovative Payment Model Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE